Total Payments
$4.0M
2024 Payments
$53,047
Companies
8
Transactions
287
Payment Breakdown by Category
Research$4.0M (100.0%)
Consulting$791.80 (0.0%)
Travel$328.66 (0.0%)
Food & Beverage$183.63 (0.0%)
Education$31.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.0M | 281 | 100.0% |
| Consulting Fee | $791.80 | 1 | 0.0% |
| Travel and Lodging | $328.66 | 1 | 0.0% |
| Food and Beverage | $183.63 | 3 | 0.0% |
| Education | $31.50 | 1 | 0.0% |
Payments by Type
Research
$4.0M
281 transactions
General
$1,336
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $2.1M | 18 | $0 (2024) |
| Allergan, Inc. | $896,907 | 102 | $0 (2022) |
| Sumitomo Pharma America, Inc. | $539,515 | 126 | $0 (2023) |
| JAZZ PHARMACEUTICALS INC. | $253,358 | 14 | $0 (2022) |
| Sage Therapeutics, Inc. | $213,591 | 7 | $0 (2020) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33,440 | 3 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $27,826 | 16 | $0 (2019) |
| Lundbeck LLC | $18.31 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $53,047 | 4 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) ($33,440) |
| 2023 | $703,378 | 130 | Sumitomo Pharma America, Inc. ($539,515) |
| 2022 | $900,341 | 25 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($614,584) |
| 2021 | $467,497 | 6 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($467,035) |
| 2020 | $1.1M | 51 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($588,985) |
| 2019 | $762,555 | 60 | Allergan Inc. ($543,330) |
| 2018 | $6,370 | 11 | Sunovion Pharmaceuticals Inc. ($6,288) |
All Payment Transactions
287 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | — | — | Cash or cash equivalent | $10,504.59 | Research |
| Study: A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment | ||||||
| 10/07/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | — | — | Cash or cash equivalent | $10,185.52 | Research |
| Study: A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment | ||||||
| 07/22/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | — | — | Cash or cash equivalent | $12,750.00 | Research |
| Study: A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment | ||||||
| 01/18/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | Cash or cash equivalent | $19,607.21 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN THE TREATMENT OF ADULTS WITH POST?TRAUMATIC STRESS DISORDER • Category: PSYCHIATRY | ||||||
| 12/15/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $1,212.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/15/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $370.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/15/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $352.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/15/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $324.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/11/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $10,989.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/11/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $9,297.50 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/11/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $5,554.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/11/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $5,554.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/11/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $5,554.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/11/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $5,554.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/11/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $5,554.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/11/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $5,554.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/11/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $5,264.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/11/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $5,264.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/11/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $4,239.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/11/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $3,510.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/11/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $3,510.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/11/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $3,510.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/11/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $3,510.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/11/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $3,510.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
| 12/11/2023 | Sumitomo Pharma America, Inc. | — | — | Cash or cash equivalent | $2,754.00 | Research |
| Study: A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder • Category: CNS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTI-CENTER, RANDOMIZED, CONTROLLED TRIAL TO EVALUATE THE EFFECTIVENESS OF A DIGITAL THERAPEUTIC (CT-152) AS ADJUNCTIVE THERAPY IN ADULT SUBJECTS DIAGNOSED WITH MAJOR DEPRESSIVE DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $736,590 | 4 |
| A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | Sumitomo Pharma America, Inc. | $539,515 | 126 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $501,900 | 5 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (TRIAL 405-201-00013) | Otsuka Pharmaceutical Development & Commercialization, Inc. | $258,733 | 1 |
| A MULTICENTER PHASE 2 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED PARALLEL-GROUP STUDY OF JZP150 FOR THE TREATMENT OF POSTTRAUMATIC STRESS DISORDER | JAZZ PHARMACEUTICALS INC. | $253,358 | 14 |
| A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel in the Prevention of Relapse in Patients with Major Depressive Disorder | Allergan Inc. | $250,328 | 10 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | Allergan, Inc. | $225,265 | 17 |
| BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $201,625 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $165,679 | 1 |
| 217-MDD-303 | Sage Therapeutics, Inc. | $151,448 | 2 |
| AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $124,945 | 1 |
| A Randomized, Double-Blind, Placebo-and Active-Controlled, Multicenter Study of Rapastinel as Monotherapy in Patients with Major Depressive Disorder | Allergan Inc. | $99,903 | 10 |
| PHASE IIA US POP W SOD 3125-201-002 | Allergan Inc. | $99,888 | 6 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | Allergan, Inc. | $60,720 | 10 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | Allergan Inc. | $51,698 | 13 |
| A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER | Sage Therapeutics, Inc. | $46,054 | 2 |
| A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | Allergan, Inc. | $39,917 | 15 |
| A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33,440 | 3 |
| AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $32,008 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | Allergan Inc. | $25,345 | 5 |
| Dasotraline Binge Eating Disorder Extension Study | Sunovion Pharmaceuticals Inc. | $21,538 | 8 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN THE TREATMENT OF ADULTS WITH POST?TRAUMATIC STRESS DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $19,607 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE WHO HAVE PREVIOUSLY FAILED 2 | Allergan, Inc. | $15,149 | 3 |
| A PHASE 3, MULTICENTER, OPEN-LABEL 52-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH CHRONIC OR EPISODIC MIGRAINE | Allergan, Inc. | $12,000 | 3 |
| 217-MDD-302 | Sage Therapeutics, Inc. | $9,551 | 1 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | Allergan Inc. | $7,831 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SAGE-217 WITH A FIXED, REPEATED TREATMENT REGIMEN ON RELAPSE PREVENTION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | Sage Therapeutics, Inc. | $6,538 | 2 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. | Otsuka Pharmaceutical Development & Commercialization, Inc. | $6,200 | 1 |
| AN OPEN LABEL, LONG TERM-EXTENDED ACCESS PROTOCOL FOR RAPASTINEL AS ADJUNCTIVE OR MONOTHERAPY TREATMENT IN PATIENTS WITH MAYOR DEPRESSIVE DISORDER | Allergan Inc. | $5,000 | 1 |
| A PHASE 3, 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM, FIXED-DOSE TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE (OPC34712) IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMERS TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $3,682 | 1 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis | Sunovion Pharmaceuticals Inc. | $3,371 | 2 |
| A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | Allergan Inc. | $2,678 | 3 |
| Pediatric Open-Label Extension Study | Sunovion Pharmaceuticals Inc. | $2,077 | 4 |
| A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures | Sunovion Pharmaceuticals Inc. | $840.01 | 2 |
| A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE | Allergan Inc. | $660.00 | 1 |
About Dr. Donald Garcia, MD
Dr. Donald Garcia, MD is a Psychiatry healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/20/2010. The National Provider Identifier (NPI) number assigned to this provider is 1881925568.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Donald Garcia, MD has received a total of $4.0M in payments from pharmaceutical and medical device companies, with $53,047 received in 2024. These payments were reported across 287 transactions from 8 companies. The most common payment nature is "" ($4.0M).
Ad
Practice Information
- Specialty Psychiatry
- Location Austin, TX
- Active Since 01/20/2010
- Last Updated 10/27/2011
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1881925568
Products in Payments
- REXULTI (Drug) $733,033
- VRAYLAR (Drug) $233,127
- QULIPTA (Drug) $27,149
- SEP-225289 (Drug) $21,538
- SEP-363856 (Drug) $3,371
- Latuda (Drug) $2,077
- Aptiom (Drug) $840.01
- BOTOX (Biological) $461.71
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Austin
Dr. Arvinder Pal Walia, M.d, M.D
Psychiatry — Payments: $2.7M
Psychiatry $2.7M
Charles Nemeroff, Md Phd, MD PHD
Psychiatry — Payments: $400,808
Psychiatry $400,808
Dr. Divyansu Patel, M.d, M.D
Psychiatry — Payments: $319,461
Psychiatry $319,461
Frank Floca, Md, MD
Psychiatry — Payments: $99,177
Psychiatry $99,177
Dr. Charles Sweet, M.d., M.p.h, M.D., M.P.H
Psychiatry — Payments: $88,371
Psychiatry $88,371
Dr. David Brown, M.d, M.D
Psychiatry — Payments: $45,241
Psychiatry $45,241